

PROSPECTUS SUPPLEMENT
(To Prospectus Supplement dated February 1, 2021
To Prospectus dated February 1, 2021)



Up to \$14,000,000

American Depositary Shares Representing Ordinary Shares

This prospectus supplement amends and supplements the information in the prospectus, dated February 1, 2021, filed with the Securities and Exchange Commission as a part of our registration statement on Form F-3 (File No. 333-252334), as previously supplemented by our prospectus supplement dated February 1, 2021, or the Prior Prospectus, relating to the offer and sale of up to \$60,000,000 of our American Depositary Shares, or ADSs, representing ordinary shares, pursuant to the sales agreement, or the Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., dated January 22, 2021. Each ADS represents five of our ordinary shares, or the Ordinary Shares, no par value. This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus and any future amendments or supplements thereto.

Through April 6, 2023, we have sold 1,378,344 of our ADSs in accordance with the Sales Agreement under the Prior Prospectus. We are filing this prospectus supplement to amend the Prior Prospectus because we are now subject to General Instruction I.B.5 of Form F-3, which limits the amounts that we may sell under the registration statement of which this prospectus supplement and the Prior Prospectus are a part. After giving effect to these limitations and the current public float of our ADSs and after giving effect to the terms of the Sales Agreement, we currently may offer and sell shares of our ADSs having an aggregate offering price of up to \$14,362,937 under the Sales Agreement. If our public float increases such that we may sell additional amounts under the Sales Agreement and the registration statement of which this prospectus supplement and the Prior Prospectus are a part, we will file another prospectus supplement prior to making additional sales.

Our ADSs are listed on The Nasdaq Capital Market, or Nasdaq, under the symbol "FRSX." On April 3, 2023, the last reported sale price of our ADSs on Nasdaq was \$0.4191 per ADS.

The aggregate market value of our ADSs held by non-affiliates as of April 6, 2023 pursuant to General Instruction I.B.5 of Form F-3 is \$43,088,812, which was calculated based on 59,845,572 ADSs outstanding held by non-affiliates and at a price of \$0.72 per ADS, the closing price of our ADSs on February 7, 2023. As of the date hereof, we have not offered or sold any securities pursuant to General Instruction I.B.5 of Form F-3 during the prior 12 calendar month period that ends on and includes the date hereof. As a result of the limitations of General Instruction I.B.5 of Form F-3, and in accordance with the terms of the Sales Agreement, we are registering the offer and sale of our ADSs having an aggregate offering price of up to \$14,000,000 from time to time through A.G.P.

Investing in our securities involves risks. See "Risk Factors" on page 3 of the Prior Prospectus and in the documents incorporated by reference into the Prior Prospectus and in our most recent Annual Report on Form 20-F, and any amendments thereto, which are incorporated by reference into the Prior Prospectus, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the Prior Prospectus for a discussion of the factors you should carefully consider before deciding to purchase our ADSs.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prior Prospectus, this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

A.G.P.

The date of this prospectus supplement is April 6, 2023.
